EPA-Statin Capsule for Cardiovascular Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for cardiovascular diseases are inadequate in effectively managing conditions such as high blood pressure, coronary heart disease, and stroke, necessitating the development of improved therapeutic approaches.

Innovation Solution

A pharmaceutical composition combining a fatty acid component, specifically ethyl eicosapentaenoate, with a statin, such as atorvastatin or rosuvastatin, where the statin is either encapsulated within the fatty acid component or coated on the capsule shell, ensuring controlled release and enhanced bioavailability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for cardiovascular diseases are used, then treatment is provided, but the treatments are inadequate in effectively managing conditions such as high blood pressure, coronary heart disease, and stroke

Engineering Contradiction:

Improveeffectiveness of cardiovascular disease treatmentVSAvoidability to manage multiple cardiovascular conditions

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent combines two different active ingredients (statin and EPA) into a single pharmaceutical composition delivered via a unified capsule system. This merging approach allows the treatment to address multiple cardiovascular conditions simultaneously, improving both effectiveness and versatility while simplifying the treatment regimen for patients

Inventive Principle:

Principle #5Merging (Combining)

2Reliability

If statin is encapsulated within fatty acid component or coated on capsule shell, then controlled release and enhanced bioavailability are achieved, but device complexity increases

Engineering Contradiction:

Improvebioavailability of statinVSAvoidcomplexity of capsule structure

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent utilizes a capsule shell structure that can be configured in different ways (statin encapsulated within fatty acid component, or statin coated on capsule shell). This flexible shell approach enables controlled release and enhanced bioavailability while maintaining a relatively simple overall device structure that can be manufactured using standard pharmaceutical techniques

Inventive Principle:

Principle #30Flexible shells and thin films

Data Source

PatentUS11547710B2Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin

Publication Date: 2023.01.10 AMARIN PHARMACEUTICALS IRELAND LIMITED(IE)

AI summary

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and a statin and to methods of using the same to treat or prevent cardiovascular-related diseases.